Price T Rowe Associates Inc Agios Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,832,512 shares of AGIO stock, worth $157 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,832,512
Previous 2,777,259
1.99%
Holding current value
$157 Million
Previous $120 Million
5.09%
% of portfolio
0.01%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding AGIO
# of Institutions
232Shares Held
58.1MCall Options Held
403KPut Options Held
469K-
Farallon Capital Management LLC San Francisco, CA5.66MShares$314 Million1.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.55MShares$308 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$270 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.74MShares$207 Million2.8% of portfolio
-
State Street Corp Boston, MA2.33MShares$129 Million0.0% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $3.04B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...